Angiotensin Converting Enzyme Inhibitor

This page covers all Angiotensin Converting Enzyme Inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Angiotensin-converting enzyme.

Targets

Angiotensin-converting enzyme

Marketed (8)

• Accupril · Pfizer · Metabolic
• Monopril · Metabolic
  Monopril works by blocking the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor.
• TRANDOLAPRIL
• Aceon · Symplmed Pharms Llc · Metabolic
• Cetapril · Par Pharm · Cardiovascular
• Vasotec · Azurity · Cardiovascular
  Vasotec works by blocking the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor.
• Lotensin · Validus Pharms · Metabolic
• Altace · King Pfizer · Metabolic
  Altace works by blocking the action of angiotensin-converting enzyme, a key player in the renin-angiotensin-aldosterone system that regulates blood pressure.

Patent intelligence

• angiotensin converting enzyme inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates